Menu

All Items

Page 5 of 7  

Rare disease day 2018

The personal impact of rare diseases

PPD employees, including a rare disease patient, parent and researcher, share their experiences.

Read more...
 

Proactivity in a GMP Contract Laboratory thumbnail

Proactivity in a GMP contract laboratory

Chris Forsdyke, executive director, PPD® Laboratories’ GMP lab in Athlone, Ireland, details why proactivity is important even in a regulated laboratory environment.

Read more...
 

Positive changes in the Latin American clinical trial regulatory environment

Positive changes in the Latin American clinical trial regulatory environment

Andres Bayona, executive director in clinical monitoring and regional head of Latin America, and Mercedes Ponce de Leon, senior manager in regulatory affairs, discuss the clinical trial regulatory landscape in Latin America.

Read more...
 

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Jie Ding, associate director of development and validation at the PPD® Laboratories’ GMP lab, discusses liquid chromatography-mass spectrometry in drug discovery and development.

Read more...
 

First-in-health regulatory changes Kirsten Messmer

Seeking ways to ensure participant safety in first-in-human trials

Kirsten Messmer, Ph.D., R.A.C., principal regulatory affairs specialist, details changes in regulatory guidelines for first-in-human trials.

Read more...
Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.